<DOC>
	<DOC>NCT00798707</DOC>
	<brief_summary>The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening) Hamilton Psychiatric Rating Scale for Depression (HAMD 17) total score of &gt;= 20 Clinical Global Impressions ScaleSeverity (CGIS) score of &gt;= 4 Clinical instability 25% or greater increase/decrease in HAMD 17 total score from screening to baseline Significant risk of suicide as assessed by clinician judgement, HAMD 17 and Columbia SuicideSeverity Rating Scale scores Other eligibility criteria also apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Major Depressive Disorder</keyword>
</DOC>